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Surgical Therapy of Cutaneous Melanoma
Dan G. Blazer III,a Vernon K. Sondak,b and Michael S. Sabel
For most solid tumors therapy has evolved from surgery alone to a multidisciplinary
approach. Malignant melanoma remains an exception, with surgery maintaining the prin-
cipal role not only for treatment of the primary lesion but also staging and the management
of advanced disease. The surgical management of melanoma has evolved over the years,
resulting in a substantial decrease in the morbidity associated with treatment without a
compromise in outcome. This article will review the changes that have occurred leading to
the current surgical approach to melanoma, the evidence behind these recommendations,
and new questions that need to be addressed.
Semin Oncol 34:270-280 © 2007 Elsevier Inc. All rights reserved.
With an estimated 62,190 cases in the United States in2006, cutaneous melanoma is expected to be the fifth
most common cancer in men and the sixth most common
cancer in women.1 The greatest impact that can be made on
this disease is early diagnosis through careful surveillance
and an aggressive use of biopsy for suspicious lesions. Sur-
vival is dramatically better when melanoma is discovered
early before the lesion has thickened or spread to regional
lymph nodes.
The treatment of many solid tumors has evolved over
the years from surgery alone to multidisciplinary therapy.
However, the management of melanoma remains centered
on resection. Although chemotherapy and radiation ther-
apy have made major contributions to the management of
other malignancies, their benefit in melanoma has been
limited. Biologic and immunologic therapies, while hold-
ing great promise, have yet to make a significant impact on
melanoma outcome. Thus, surgical extirpation remains
the best hope for long-term survival. This point is true not
only for early-stage disease, but also advanced regional
and, in some cases, distant disease. In this issue of Semi-




Up to 85% of patients with newly diagnosed cutaneous mel-
anoma have disease that is clinically confined to the site of the
primary lesion.2 Because local recurrence rates associated
with narrow but negative margins approach 60%,3 excision
with wide margins of normal skin has been the cornerstone of
the surgical management of primary melanoma for 150 years,
a strategy first described by William Norris in 1857.4
Although still a standard approach, the nature of the wide
excision has evolved over time. In 1907 Handley advocated
margins of 1 inch of skin and 2 inches of subcutaneous tissue
in order to prevent recurrence.4 In the latter half of the 20th
century, wider margins (4 or 5 cm) were recommended
based on the discovery of melanocytes or microsatellites be-
yond the recommended margins of excision. These radical
excisions remained the standard of care in the treatment of
melanoma for decades. However, the uncertainty of whether
or not the substantial morbidity of these wider margins really
did improve survival prompted studies to support these rec-
ommendations. Several randomized trials were initiated to
test the necessity of wide (3, 4, or 5 cm) margins over narrow
(1 or 2 cm) margins (Table 1). Current recommendations are
based on these trials, but the trials differed greatly in both the
patient populations studied and the margins examined.
Thus, while these trials taught us much about melanoma and
thereby decreased treatment morbidity, the minimum ade-
quate margin of excision is still uncertain.
The first randomized trial evaluating surgical margins for
melanomas less than 2 mm thick was the World Health Or-
ganization (WHO) Melanoma Group study.5 This trial com-
pared 1-cm versus 3-cm margins of excision in 612 patients.
Long-term results demonstrated no survival differences be-
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tween these two patient groups. For the patients with mela-
nomas 1 mm, there were no local recurrences regardless of
margin size. This trial thereby established the safety of 1-cm
margins of excision for thin melanomas. For patients with
melanomas between 1 and 2 mm, there was a 2.7% local
recurrence rate for 1-cm excision margins compared with 0%
in the 3-cm group. While this result is not statistically signif-
icant and had no survival impact, the study had insufficient
statistical power to dispel concerns regarding 1-cm excision
margins for melanomas greater than 1 mm of depth.
The next three trials compared wider (4 or 5 cm) margins
of excision to 2-cm margins for intermediate thickness mel-
anomas. The Intergroup Melanoma Surgical Trial6,7 enrolled
740 patients with intermediate-thickness (1 to 4 mm) mela-
nomas and randomly assigned 470 of these patients to either
2- or 4-cm resection margins. No statistically significant dif-
ferences in survival or local recurrence were identified, even
at 10 years. The Swedish Melanoma Study Group8 evaluated
989 patients with primary melanomas between 0.8 and 2.0
mm thickness. These patients were randomly assigned to
excision with a 2- or 5-cm margin, and again there were no
statistically significant differences in local recurrence or sur-
vival rates. Finally, the French Cooperative Group9 evaluated
326 patients with melanomas of 2 mm thickness and ran-
domly assigned them to 2- or 5-cm margins. This trial also
demonstrated no differences in local recurrence or survival
rates. Based on these study results, it is evident that margins
greater than 2 cm are unnecessary for the management of
intermediate thickness melanoma.
The British Cooperative Group Trial10 compared 1- versus
3-cm margins in 900 patients with melanoma thickness 2
mm. This randomized trial was the only one that included
patients with melanomas 4 mm thick, constituting 25% of
the total group. No statistically significant difference in over-
all survival was observed. However, a 1-cm excision margin
was associated with a significantly increased rate of local-
regional recurrence, the majority of which occurred in the
regional lymph nodes. There was also a trend, although not
significant, towards decreased survival in the 1-cm margin
group. Based on these results, the authors recommended
margins of excision wider than 1 cm for melanomas greater
than 2 mm.
Cumulatively, these trials established the fact that margins
of excision greater than 3 cm were unnecessary for the resec-
tion of primary melanoma. They demonstrate that 1-cm mar-
gins of excision are adequate for thin (1 mm) melanomas,
and 2-cm margins are appropriate for melanomas 1 mm.
However, are 2-cm margins necessary for melanomas greater
than 1 mm in thickness, or would a 1-cm margin suffice? The
argument for 2-cm margins centers on two subgroups of the
clinical trials:
● In the WHO trial melanomas between 1 and 2 mm had
a 2.7% local recurrence rate when excised with only
1-cm margins, compared to no local recurrences for
3-cm margins.
● In the British Cooperative Trial locoregional recurrence
was significantly higher in the 1-cm margin group than
the 3-cm margin group, with a trend towards improved
survival.
Does this current level of evidence support 2-cm margins?
Although there were some local recurrences in the WHO trial
for melanomas between 1 and 2 mm when only a 1-cm mar-
gin of excision was used, the difference was not statistically
significant. In addition, there was no difference in overall
survival between the two groups. For this reason, current
guidelines recommend obtaining 2-cm margins (when pos-
sible) for melanomas between 1 and 2 mm, but the margins
may be decreased to as small as 1 cm if a skin graft or exces-
sive closure tension can be avoided.
Stronger evidence for requiring a 2-cm margin for mela-
nomas 2 mm and, when possible, for melanomas between
1 and 2 mm comes from the British trial. Although there was
a significant increase in local-regional recurrences with 1-cm
margins, this result only achieved statistical significance
when local and regional recurrences were added together. If
one looks only at the local recurrence rate, there was no
difference between the 2 treatment arms. Most of the recur-
rences were, in fact, regional. However, the trial was limited
to wide local excision alone; patients undergoing elective
lymph node dissection or sentinel lymph node (SLN) biopsy
were not included. We now need to consider how these trial
results might have changed if the current routine practice of
SLN biopsy had been used during these studies.
Proponents of the 2-cm margin argue that the wider exci-
sion in the British trial, by incorporating the microscopic
disease that was present outside of the 1-cm radius, pre-
vented this disease from ultimately reaching the lymph











WHO Melanoma Program, 19915 612 1 3 <2 NSD OS, DFS, LRR
Intergroup Melanoma Surgical Trial, 19966,7 470 2 4 1–4 NSD OS, LRR
Swedish Melanoma Group, 20008 989 2 5 0.8–2 NSD OS, DFS, LRR
French Cooperative Group, 20039 326 2 5 <2.1 NSD OS, DFS
United Kingdom Melanoma Group, 200410 900 1 3 >2 NSD OS
Increased LRR with 1-cm margins
(HR  1.26, P  .05).
Abbreviations: NSD, no significant difference; OS, overall survival; DFS, disease-free survival; LRR, local-regional recurrence; HR, hazard ratio.
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then have been no difference in regional recurrence between
the two groups. Any difference in the SLN positivity rate
between the two groups would have been ascribed to uneven
randomization, thereby causing any trend towards decreased
survival. Had SLN biopsy been employed, conclusions of the
trial would arguably have been the opposite (that there is no
negative impact on either local recurrence or overall survival
of 1-cm margins), and this approach may have become the
standard of care for melanoma wide excisions.
To put an end to the conjecture, a sixth trial is needed: a
randomized trial between 1- and 2-cm margins for interme-
diate thickness melanoma. While such a trial has been pro-
posed, it may not be practical because of the very large num-
ber of patients required to demonstrate equivalence.
Whether or not that is appropriate is controversial, given the
limited resources available for clinical research. However,
without such a trial we are left wondering about the necessity
for routine 2-cm margins. Is the resultant effect on aesthetics
and the need for skin grafting over-treatment?
Based on the evidence described above, the recommended
margins of excision are listed in Table 2. Technically, wide
excision involves marking the proper radial margin circum-
ferentially around the lesion or the site of the biopsy (Fig. 1).
Margins should be measured in each direction from the pe-
riphery of the lesion or scar rather than from the center. This
technique typically results in a circular or oval area of resec-
tion, which would be difficult to close primarily. Thus, an
ellipse is created that incorporates this circle. The long axis is
typically oriented to best facilitate primary closure, eg, longi-
tudinally along an extremity. The long axis is often deter-
mined by the orientation of the initial biopsy, which is why it
is important to always plan for eventual wide radical excision
when performing an excisional biopsy of an atypical skin
lesion. Although a length to width ratio of approximately
3.5:1 or 4:1 is optimal for the ellipse, this ratio may result in
an exceptionally long scar. A ratio of 3:1 is usually adequate
to avoid “dog-earing,” but this problem can also be corrected
by the use of a V-plasty.
While the radial excision margin is important, the depth of
excision must also be considered. Historically, some sur-
geons have believed that excising the underlying muscular
fascia might promote the dissemination of tumor cells and
increase the recurrence rate.11 No prospective trials have ever
addressed this question. A retrospective trial12 published in
1982 found no significant difference in survival or local re-
currence for patients in whom fascia was preserved versus
patients in whom the fascia was removed. The current prac-
tice is excision of cutaneous and subcutaneous tissue down
to, but not including, the underlying fascia. Some surgeons
advocate removal of the underlying fascia en bloc when the
previous surgical biopsy closely approaches or includes the
underlying fascia.
Most wide excisions of primary melanoma can be closed
primarily. Skin flaps are raised in the plane above the deep
fascia to alleviate tension. Closure is performed in two layers.
Interrupted deep dermal absorbable sutures should be fol-
lowed by a running subcuticular stitch, or nylon sutures,
depending on the skin tension and the anticipated motion
effects. When the wound cannot be closed primarily, more
complex coverage techniques must be employed such as skin
grafting or use of local and distant flaps. If advancement flaps
can be used, this is preferable to skin grafts, because patient
acceptance of cosmesis has more to do with the soft tissue
indentation than the length of the incision.13 If complex flaps
may be necessary for wound coverage, preoperative planning
with a plastic surgeon is warranted. Flaps can offer an excel-
lent color match, durability, and overall cosmesis.
Skin grafting may be either split-thickness or full-thick-
ness, depending on recipient location. The skin graft donor
site should preferentially be outside the area of potential in-
transit metastases. Partial thickness skin grafts are obtained
using a dermatome calibrated to harvest 0.12 to 0.18 inch,
Table 2 Recommended Surgical Margins for Excision of Pri-
mary Melanoma
Melanoma Thickness (mm) Excision Margin (cm)
In situ 0.5
<1.0 1.0
1.01–2.0 1.0 to 2.0
2.01–4.0 2.0
>4.0 At least 2.0
Figure 1 Wide excision of melanoma. Appropriate margins are measured around the melanoma or biopsy scar. An
ellipse is then created that incorporates the area with a length to width ratio of at least 3 to 1. Obtaining a 2-cm margin
around a melanoma (or biopsy site) 1 cm in diameter results in a scar length of 15 cm.
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which provides epidermis and partial dermis. The graft can
be meshed, if necessary, to fill a large defect. If meshing is not
performed, several small incisions should be made with a
scalpel to prevent seroma formation underneath the graft.
The graft is then secured to the wound by staples or sutures.
It is critical that the entire surface of the graft adhere to the
wound base for the first few days for the graft to survive.
Stable adherence can be achieved with a gently compressive
bolster and a splint for the extremity. The bolster is usually
taken off to allow the graft to be examined 3 to 5 days after
placement.
Full-thickness grafts encompass the entire epidermis and
dermis, and they tend to contract less and give better cosme-
sis. For most patients with melanoma (even thin patients)
adequate full-thickness grafts can be easily obtained from
areas of redundant skin (supraclavicular, lower hypogastric,
inguinal, axillary) to fill most resultant defects. The graft can
often be obtained from the SLN biopsy region, thus preclud-
ing the need for a third incision. It is important to orient the
donor site incision carefully so that it can be re-excised with
a subsequent node dissection if the sentinel node is positive.
Full-thickness grafts should be used in the head and neck
region, but split-thickness skin grafts are preferred for the
scalp. Skin grafts to the face should be carefully matched for
color and texture.
Melanomas arising on the skin or nail bed of the toes are
managed with a straightforward amputation at the metatar-
sophalangeal joint. Lesions that arise between two toes often
require amputation of both adjoining toes. When melanomas
arise on the fingers, surgeons attempt to preserve as much of
the digit as possible without compromising margins. Typi-
cally, amputations are performed at the middle interphalan-
geal joint of the fingers or proximal to the distal joint of the
thumb. One exception to this is the index finger, where am-
putation of the digit at the middle interphalangeal joint can
interfere with the patient’s grasp. A more cosmetically pleas-
ing and more functional outcome can often be achieved with





All patients with melanoma should undergo a careful physi-
cal examination, with special attention being paid to the re-
gional draining, lymph node basins. Between 5% and 10% of
patients have clinical evidence of nodal metastases when first
diagnosed with melanoma.14 Surgical excision of palpable
regional lymph node disease can be potentially curative. In
addition, resection of nodal disease can palliate pain and
prevent skin breakdown.
When clinically suspicious nodes (generally 1 cm, hard
or fixed to adjacent structures) are present in a patient with
melanoma or a history of melanoma, fine-needle aspiration
(FNA) biopsy is recommended, because it is highly accurate
and does not interfere with the subsequent dissection. Open
biopsy complications (seroma, infection, or hematoma) and
the need to excise the resultant scar, may not only worsen the
morbidity of the definitive operation but increase the risk of
local recurrence.15 Excisional biopsy should be reserved for
cases where the FNA biopsy results are inconclusive. The
biopsy incision should be oriented in a way that it can be
easily incorporated into the resection margins. In addition,
given the high likelihood of distant disease and the morbidity
of the operation, a metastatic work-up should be initiated
prior to surgery. At a minimum, patients should have a com-
plete history and physical examination, chest radiograph,
and serum lactate dehydrogenase with any abnormalities
prompting a more thorough search. However, most surgeons
advocate routine imaging in asymptomatic patients, consist-
ing of either computerized tomography (CT) scans of the
chest, abdomen and pelvis, 18-flourodeoxyglucose positron
emission tomography (FDG-PET), or a CT-PET study. In
many cases these radiographs will upstage stage III patients to
stage IV, which will alter the therapeutic approach.16-18
For patients with cervical metastases from epithelial ma-
lignancies, the gold standard has been the radical neck dis-
section to remove all ipsilateral cervical lymph nodes in levels
I–V. The spinal accessory nerve, internal jugular vein, and
sternocleidomastoid muscle are removed as well. However,
several studies have demonstrated no significant differences
in regional control of melanoma with the modified radical
versus radical approaches.19-21 The modified radical neck dis-
section removes all lymph nodes routinely excised in a radi-
cal neck dissection but, at a minimum, preserves the spinal
accessory nerve and attempts to preserve the internal jugular
vein and sternocleidomastoid muscle. A parotidectomy and
neck dissection are advocated for patients with parotid nodal
involvement.
When palpable disease is evident in the axilla, axillary
lymph node dissection (ALND) is used to remove levels I and
II nodes completely and at least some level III nodes. The
thoracodorsal neurovascular bundle and long thoracic nerve
are spared. In the cases of minimal disease burden, it may be
adequate to remove only levels I and II nodes. To access
clinically involved level III nodes, it is often necessary to
divide the pectoralis minor muscle. However, some surgeons
believe clinically uninvolved level III nodes can be removed
adequately by retraction of the pectoralis muscle without
actual division. The intercostobrachial nerves may also be
preserved, although most surgeons routinely resect these
nerves when palpable disease is present, causing paresthesias
of the upper inner arm. Brachial plexus injuries are rare but
devastating complications, so great care is taken to avoid
them.
A complete axillary dissection even in the most experi-
enced hands carries significant morbidity. The most com-
mon long-term complication is lymphedema, which can
be quite disabling and occurs to some degree in at least
10% of cases.22,23 Preserving the muscle fasciae from the
pectoralis and latissimus dorsi muscles during the dissection,
or avoiding skeletonization of the axillary vein (which some
surgeons consider essential), may decrease lymphedema
rates.24
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When disease is present in the groin, the extent of the node
dissection is controversial. A superficial inguinal lymph node
dissection (ILND) is performed by removing the fibrofatty
node-bearing tissue inferior to the inguinal ligament and be-
tween the adductor muscle and the sartorius muscles. The
tissue superficial to the external oblique fascia from the level
of the anterior superior iliac spine laterally to the pubic tu-
bercle medially also contains lymph nodes and is included in
the dissection. When palpable nodal disease is present, some
surgeons routinely excise the pelvic nodes. These nodes can
be removed en bloc by incising the external oblique fascia,
dividing the inguinal ligament, or making a separate midline
laparotomy incision. This procedure is typically referred to as
a deep dissection, which adds removal of the iliac nodes to the
inguinofemoral nodes. Other surgeons take a more selective
approach to a deep dissection. Some surgeons recommend
that if the node between the inguinal and iliac chains (Clo-
quet’s node) is removed and found to harbor metastatic dis-
ease, then a deep dissection should be performed en bloc
with the superficial dissection. Unfortunately, the absence of
disease in Cloquet’s node does not always predict the absence
of involvement of iliac nodes.25 Other selection criteria for
deep dissection are enlarged pelvic nodes by CT scan and
three or more metastatic lymph nodes found in the superfi-
cial dissection.
Whether the more extensive dissection confers a survival
advantage remains unknown. In a retrospective review of
104 patients who underwent either combined superficial
with deep dissection or superficial dissection only for palpa-
ble groin disease, the extent of surgery did not influence
survival or local control rates.26 In another retrospective re-
view of 227 patients having superficial versus superficial plus
deep inguinal lymphadenectomy, the extent of surgery was
not associated with a survival difference, and these authors
recommended superficial plus deep dissection only in pa-
tients with clinical or radiologically positive deep nodal dis-
ease.27
The morbidity of groin dissection is more substantial than
axillary dissection, with complication rates between 50% and
60%.7,28 Wound complications are common with an ILND
and include skin flap necrosis, wound infection, and dehis-
cence. Lymphedema rates are approximately 20% to
30%.29-31 Preservation of the saphenous vein or preservation
of muscle fasciae from the adductor during dissection may
also decrease the rate of lymphedema but is rarely feasible in
the node-positive groin dissection. Most surgeons advocate
use of 20 to 30 mm Hg compression hose for several months
postoperatively. These hose should be obtained preopera-
tively, when the extremity circumference is normal, rather
than postoperatively when edema may have already partially
developed.
Regional Management of the
Clinically Node-Negative Patient
Most patients who present with primary melanoma have clin-
ically negative (non-palpable) regional lymph nodes, but as
many as 20% to 30% of these patients harbor occult regional
nodal metastases. Before the description by Morton et al32 in
1992 of the technique of lymphatic mapping and SLN biopsy
in melanoma cases, much controversy existed surrounding
the management of the nodal basin. With the understanding
that primary melanomas often spread to regional nodal ba-
sins before metastasizing widely, some surgeons advocated
elective lymph node dissection (ELND), with the idea that
early clearance of tumor deposits in the regional nodal basin
could prevent subsequent dissemination and improve sur-
vival. However, given the significant morbidity of nodal
clearance from regional nodal basins, there was much inter-
est in knowing whether or not ELND provided true benefit.
While retrospective data suggested a survival benefit for
ELND,33,34 four prospective trials failed to demonstrate
this.35-38 However, some data suggested that there might be
subsets of patients who did benefit. The Intergroup Mela-
noma Surgical Program randomized 740 stage I and II pa-
tients to ELND or observation.36 While there was no overall
difference in survival between the two groups, in a subgroup
analysis ELND conferred a survival benefit in patients with
non-ulcerated melanomas and in patients with tumor thick-
ness between 1 and 2 mm. Further evidence comes from the
WHO Melanoma Group Program 14 trial, which randomized
patients with truncal melanoma to wide excision plus ELND
or wide excision plus observation, with node dissection being
done if patients subsequently recurred.37 Again, there was no
overall survival benefit, but when survival of patients with
microscopic disease on ELND were compared with those
who had regional recurrences, the survival was significantly
improved in the ELND group (48.2% v 26.6%, P  .04).
These data suggest, but do not prove, that node dissection
will improve survival among those patients who harbor mi-
croscopic disease. There was no accurate way during these
trials to identify such patients, but the introduction of lym-
phatic mapping and SLN biopsy has dramatically changed
that point. The technique is a minimally invasive procedure
that identifies patients with occult microscopic disease and is
best performed at the time of wide local excision of the pri-
mary lesion. The hypothesis underpinning the technique is
that melanoma involvement of a nodal basin develops in an
orderly fashion with metastasis to the SLN as the first step in
the process.39 Identification and removal of the SLN will ac-
curately stage that nodal basin and, in turn, identify those
patients who would benefit from full node dissection, while
preventing node-negative patients from undergoing a sub-
stantially morbid procedure.40 The accuracy of the SLN in
reflecting the pathologic status of the entire regional basin
has been confirmed in multiple studies.39,41,42
There are two common methods for identifying the SLN: a
blue dye (1% isosulfan blue, Lymphazurin, Tyco Healthcare,
Norwalk, CT) and a radiolabeled colloid solution (99m tech-
netium–labeled sulfur colloid). The radiolabeled colloid is
injected 1 to 4 hours preoperatively, and the blue dye is
injected intradermally at the site of the primary tumor a few
minutes before the SLN biopsy incision is made. The surgeon
then uses a hand-held gamma probe to mark the “hot spot”
location of the SLN, thereby minimizing the skin incision
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size. Once the incision is made, the surgeon identifies the
SLN by either following blue-stained lymphatics or by find-
ing the areas with the highest radioactive signal. The com-
bined use of the blue dye and radiolabeled colloid correctly
identifies the sentinel node in more than 95% of cases. Mor-
bidity for lymphatic mapping and SLN biopsy is much lower
than complete lymph node dissection.
In addition to preventing unnecessary lymphadenecto-
mies, SLN biopsy also provides more accurate staging. The
SLN undergoes serial step-sectioning for routine hematoxy-
lin and eosin (H&E) staining as opposed to simple bivalving
the node, as is typical with full lymphatic dissections. If serial
sectioning and H&E staining are negative for metastasis, then
immunohistochemical staining for melanoma markers such
as S-100, Melan-A, and HMB-45 is performed. With this
increased sensitivity, SLN status is now the most important
predictor of recurrent disease and survival for patients with
melanoma.
Currently, SLN biopsy is considered the standard of care
by most surgical oncologists for staging the regional lymph
nodes of patients with primary cutaneous melanomas 1.0
mm thickness. Patients with thin melanomas (1.0 mm)
have a low incidence of regional metastases, so SLN biopsy is
not routinely recommended. However, in some cases the
presence of adverse prognostic features (ulceration, Clark
level, high mitotic rate, young patient age, angiolymphatic
invasion, or Clark’s level IV or V tumors) may prompt SLN
biopsy in patients with thin melanomas.43,44 The incorpora-
tion of SLN biopsy into the surgical therapy of melanoma is
illustrated in (Fig. 2).
Does SLN biopsy with subsequent lymph node dissection
improve outcome? This issue is being addressed by the Mul-
ticenter Selective Lymphadenectomy Trial I (MSLT-I), which
randomized patients to wide excision alone or wide excision
plus SLN biopsy, with complete lymph node dissection
(CLND) for patients with a positive SLN. Interim results
demonstrate that the 5-year survival for patients who had a
CLND for a positive SLN (including false negative patients;
those patients who had a regional recurrence despite a neg-
ative SLN) was significantly better than for those patients
undergoing CLND for a recurrence after wide excision alone
(66.2% v 54.2%; HR 0.62; 95% CI, .40 to .95; P  .02).45
This result provides further evidence that CLND may im-
prove survival for the subset of patients with occult metasta-
ses. Final results from the MSLT-I trial are still pending.
A still unresolved question is how much the subsequent
CLND benefits the patient over and above the SLN biopsy
itself. In many patients the SLN will be the only nodal site in
which disease is identified pathologically and is thus thera-
peutic by itself. Approximately 70% to 90% of patients have
no detectable disease in the non-sentinel nodes removed at
the time of dissection, although “non-sentinel” nodes are not
subjected to the same intense pathologic scrutiny as are the
sentinel nodes. While there is much interest in identifying
Figure 2 Surgical management of primary melanoma. Adverse factors include angiolymphatic invasion, young patient
age, high mitotic rate, ulceration, or Clark level IV or V. WLE, wide local excision; SLNB, sentinel lymph node biopsy;
LND, lymph node dissection; HDI, high-dose interferon; Tx, treatment.
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those patients that may not require CLND, predicting which
patients will have residual disease has proven unreliable.46-48
This question is being prospectively addressed in the Multi-
center Selective Lymphadenectomy Trial II (MSLT-II), which
randomizes patients with a positive SLN to CLND or obser-
vation with serial ultrasounds of the regional node basin.
Satellite Lesions
and In-Transit Metastases
In- transit metastases and satellitosis develop in 5% to 8% of
patients with melanoma thickness greater than 1.5 mm.49
Historically, satellite lesions were defined as skin involve-
ment within 2 cm of the primary lesion, whereas in-transit
metastases were lesions between the primary tumor and a
regional lymph node basin but greater than 2 cm from the
primary tumor. These lesions were considered and treated
separately. However, Singletary et al50 demonstrated in a ret-
rospective review of 135 patients with regional cutaneous
metastases that classifying the lesions as satellites or in-transit
metastases on the basis of distance from primary tumor had
no prognostic significance. Both portend a poor prognosis.
The current American Joint Committee on Cancer (AJCC)
staging system classifies both as Stage III disease, and we will
consider these lesions together (Table 3). Surgical therapies
for in-transit disease primarily involve three strategies: local
excision or ablative therapies, isolated limb perfusion (ILP),
or isolated limb infusion (ILI).
When the number of lesions is small and the affected area
confined, optimal management is complete surgical exci-
sion.51 A specific margin of excision is not required, but his-
tologically complete removal of the metastases should be the
goal. Because distant metastatic disease is often present in
patients with in-transit disease, a metastatic work-up before
resection is recommended. When the number or location of
the in-transit lesions preclude surgical resection, intrale-
sional therapies may be employed, but the response rates are
low and their durations generally short.49,52 Given the avail-
ability of extremity perfusion strategies, intralesional thera-
pies are more frequently used for lesions on the trunk or head
and neck. Other local treatment modalities such as radiother-
apy, cryotherapy, electrodessication, and laser ablation also
have been used and have been effective in selected situa-
tions.53
When the number of lesions is beyond surgical resection in
the extremity, patients may be candidates for ILP. ILP con-
sists of regional administration of high-dose chemotherapy
(doses up to 15 to 25 times higher than systemic therapy)
within an extremity using an extracorporeal membrane oxy-
genator similar to cardiac surgery.51 Isolation of the vessels is
obtained surgically, a tourniquet is applied to prevent leak-
age of chemotherapy systemically. Using the bypass machine,
Table 3 Melanoma TNM Classification
T Classification Thickness (mm) Ulceration Status
T1 <1.0 a: Without ulceration and level II/III
b: With ulceration or level IV/V
T2 1.01–2.0 a: Without ulceration
b: With ulceration
T3 2.01–4.0 a: Without ulceration
b: With ulceration
T4 >4.0 a: Without ulceration
b: With ulceration
N Classification No. of Metastatic Nodes Nodal Metastatic Mass
N1 1 node a: Micrometastasis*
b: Macrometastasis†
N2 2 or 3 nodes a: Micrometastasis*
b: Macrometastasis†
c: In transit metastasis(es)/satellite(s) without
metastatic nodes
N3 4 or more metastatic nodes, or matted nodes,
or in transit metastasis(es)/satellite(s) with
metastatic node(s)
—
M Classification Site Serum LDH Level
M1a Distant skin, subcutaneous or nodal metastasis Normal
M1b Lung metastases Normal
M1c All other visceral metastases Normal
Any distant metastasis Elevated
Abbreviations: LDH, lactate dehydrogenase; TNM, tumor, node, metastasis.
*Micrometastases are diagnosed after sentinel or elective lymphadenectomy.
†Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or nodal metastasis that
exhibits gross extracapsular extension.
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the limb is heated to 38–40oC with high concentration che-
motherapy perfusate. After the treatment, which usually lasts
60 to 90 minutes, the drug is flushed from the circulation,
and systemic circulation is restored. The most common che-
motherapeutic agent employed has been melphalan. Using
this regimen, overall response rates between 80% and 90%
and complete response rates between 55% and 65% are ob-
tained.51 The duration of response is typically 9 to 12
months, but a subgroup of complete responders (which is
20% to 25% of the total patient population) can have sus-
tained complete responses. Toxicities range from mild ery-
thema and edema to extensive epidermolysis, functional im-
pairment, and sometimes even a need for amputation.
ILI is a less invasive and less toxic strategy for management
of in-transit metastases of the extremity; this technique was
developed in Australia approximately 12 years ago.53,54 Ac-
cess is gained to the circulation of the affected limb by stan-
dard percutaneous radiologic techniques. Arterial and ve-
nous catheters are then connected to a simple extracorporeal
circuit incorporating a heating coil. A tourniquet is inflated
around the proximal limb. The chemotherapeutic agent is
then infused into the isolated limb, although at lower doses
than those used with ILP because there will be some systemic
leakage. In one series using melphalan and dactinomycin, the
overall response in limbs treated by ILI was 85%, with a
complete response of 41% and a partial response of 44%.
Median duration of response was 16 months, results that
compare favorably to the more invasive and complex tech-




Up to one third of patients with melanoma develop distant
metastatic disease with limited options for therapy and a poor
prognosis, with a 5-year survival rate of less than 10%. While
surgery is rarely considered for most patients with solid tu-
mor metastases, melanoma remains an exception, with doc-
umented long-term survivals among some patients who un-
dergo resection of metastatic lesions. While most patients
will not be candidates for resection, selected patients should
be considered for surgery.
Careful selection for surgery of patients with stage IV mel-
anoma is imperative. The decision should be made on the
locations of the metastases, the number of lesions, morbidity
of the operation(s), the disease-free interval, and the overall
health and prognosis of the patient. Before surgery, the phy-
sician should carefully search for additional metastatic dis-
ease by performing the following: a thorough history and
physical examination, serum lactate dehydrogenase, CT
scans, magnetic resonance imaging (MRI) of the brain, and/or
a FDG-PET scan.
Soft Tissue Metastases
The most common site of distant melanoma metastases are
remote areas of skin and soft tissue, including lymph nodes
outside of the draining basins. These patients have better
outcomes compared to those with visceral metastases, with a
5-year survival of 19%. There should be no hesitancy to
resect isolated dermal or subcutaneous metastases if techni-
cally feasible, because these patients may have a reasonable
long-term prognosis; 5-year survivals of 15% to 50% have
been described (Table 4). Because resection may also be pal-
liative, erring on the side of an aggressive surgical approach is
often reasonable. Patients with more extensive soft tissue dis-
ease should be evaluated on an individual basis.
Lung Metastases
Fifteen to 30% of melanoma metastases will occur in the
lungs. Several reported series have demonstrated the feasibil-
ity of, and the improved survival from, pulmonary metasta-
sectomy in this setting (Table 5). In a series of 945 patients
with pulmonary metastatic melanoma from the Duke Univer-
sity Medical Center, 99 underwent partial or total resection.55
Survival was significantly better after complete pulmonary
resection than with no resection. For isolated pulmonary
metastases, the 5-year survival rate was 4% for patients who
did not undergo resection and increased to 20% for those
who underwent complete metastasectomy. At the M.D.
Anderson Cancer Center 56 patients underwent pulmonary
metastasectomy.56 Actuarial survival was 25% at 5 years with
a median survival of 18 months.
Liver Metastases
Cutaneous melanoma metastasizes to the liver in 15% to 0%
of patients with stage IV disease. The role of surgical resection
Table 4 Survival After Complete Resection of Skin and Soft
Tissue Metastases
First Author and Year Site (N)
5-Year
Survival
Markowitz, 199163 Soft tissue (60) 49%
Lymph nodes (72) 38%
Gadd, 199264 Skin, soft tissue,
lymph nodes (190)
14%
Karakousis, 199565 Lymph nodes (23) 22%
Subcutaneous (27) 33%
Meyer, 200066 Lymph nodes (45) 20%
Subcutaneous (30) 18%
Table 5 Survival After Complete Resection of Pulmonary
Metastases
First Author and Year N
5-Year
Survival
Wong, 198867 38 31%
Gorenstein, 199156 56 25%
Harpole, 199255 98 20%
Karakousis, 199565 39 14%
Tafra, 199568 106 27%
La Hei, 199669 83 22%
Leo, 200070 282 22%










   
co
py
for such patients is controversial. Some have argued that the
prognosis of metastatic disease to the liver is so dismal resec-
tion of metastases is not worthwhile. However, a recent
multi-institutional retrospective study57 of hepatic resection
for metastatic melanoma with curative intent evaluated 40
patients with cutaneous (n  24) or ocular melanoma (n 
16). Tumor recurred in the liver or systemically in 75% of
these patients. There were no long-term survivors in patients
with cutaneous melanoma, but the 5-year survival of patients
with metastatic ocular melanoma was 20.5%.57 These data
are limited by lack of appropriate controls but suggest that
properly selected patients may benefit from resection, given
the dismal median survival (only 2 to 7 months) of patients
with hepatic melanoma metastases. Historically, only about
2% of patients with metastatic melanoma to the liver have
been candidates for surgical resection. However, liver surgery
results have improved significantly over the past decade,
causing expansion of the criteria for resection. As regionally
directed therapy options to the liver expand, surgery for
management of patients with melanoma metastatic to the
liver may play a greater role.
Gastrointestinal Tract Metastases
In one large series, resection of melanoma from the gastroin-
testinal (GI) tract represented 16% of all metastasectomies.
GI tract metastases are often associated with disseminated
disease and, when documented, the median survival is usu-
ally only 5 to 11 months. These metastases often present with
symptoms including abdominal pain, bleeding, or obstruc-
tion, and surgical intervention is clearly indicated for pallia-
tion of these problems. However, in some of these cases a
survival advantage may also be realized. In one retrospective
review58 of 124 patients who presented with symptomatic GI
tract metastases (metastatic melanoma to the stomach, small
intestine, colon, or rectum), 69 underwent surgical explora-
tion and, of these, 46 underwent curative resection and 23
had a palliative procedure. Palliation of symptoms was excel-
lent. The median survival in patients undergoing curative
resection was 48.9 months, compared to only 5.4 months
and 5.7 months in those undergoing palliative procedures
and nonsurgical interventions, respectively. In other series,
long-term survivors up to 20 years have been reported when
undergoing surgical excision of a solitary GI metastasis.59-62
Brain and Spinal Cord Metastases
Up to 60% of patients with metastatic melanoma develop
clinically evident brain metastases at some time in their
course. Brain metastases account for 20% to 54% of the
deaths from melanoma and, when untreated, median sur-
vival is only 1 to 2 months.1 Surgical excision is favored over
whole brain irradiation for larger (3.5 cm) symptomatic
metastases and may be sometimes indicated when several
foci of metastatic disease are present. Stereotactic radiosur-
gery has gained popularity for treating smaller (3 cm) le-
sions. Surgical excision of brain metastases may improve sur-
vival up to an average of 6 months, but the main role of
surgery in this grim situation remains symptom control, not
cure. Long-term success is very uncommon.
In summary, for stage IV melanoma, selected patients with
limited sites and numbers of metastases should be considered
for complete surgical resection regardless of the location of
the disease. In general, patients with non-visceral metastatic
disease (skin and subcutaneous metastases and distant nodal
disease) amenable to resection fare better than patients with
visceral disease (lung, liver, GI tract). Patients with single
versus multiple lesions, and patients with longer disease-free
intervals between the primary tumor and the development of
stage IV disease also fare better.
Conclusions
Surgery plays an important role in the management of mela-
noma at all stages. Surgery for early-stage disease is not only
therapeutic, but with the advent of sentinel lymph node bi-
opsy, is instrumental in the staging of disease. Surgery is also
indicated in selected patients with advanced regional or dis-
tant disease for palliative purposes and occasionally curative
effect. As new chemotherapeutic agents, biologic agents, and
immunotherapies emerge and demonstrate their potential,
the objectives and indications for surgery will certainly
change, but until that time, surgical therapy remains the cor-
nerstone of therapy for malignant melanoma.
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